Meeting
2024 ASCO Annual Meeting
Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.
Authors
Stephen Oh
Washington University School of Medicine in St. Louis, St. Louis, MO
Stephen Oh , James K. McCloskey , Marta Sobas , Sarah Buckley , Purvi Suthar , Karisse Roman-Torres , Aaron Thomas Gerds
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT02055781
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6577)
DOI
10.1200/JCO.2024.42.16_suppl.6577
Abstract #
6577
Poster Bd #
136
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.
First Author: Pankit Vachhani
Poster
2023 ASCO Annual Meeting
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
First Author: Aaron Thomas Gerds
Poster
2023 ASCO Annual Meeting
Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.
First Author: Yi Zhang
Poster
2023 ASCO Annual Meeting
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).
First Author: Yi Zhang